» Articles » PMID: 6355090

Matrix Sialoprotein of Developing Bone

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1983 Oct 25
PMID 6355090
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Using nondegradative isolation procedures, we purified and characterized a glycoprotein from fetal calf bone that is rich in sialic acid. This bone sialoprotein (BSP) has an apparent Mr = 70,000-80,000 and stains with Alcian blue and Stains All on sodium dodecyl sulfate gels but does not stain with Coomassie blue without prior treatment with neuraminidase. This glycoprotein contains 50% protein, 12% sialic acid, 7% glucosamine, and 6% galactosamine. Fetal calf BSP is rich in glutamate (19%), aspartate (15.4%), and glycine (11.8%) but, in contrast to osteonectin and the bone proteoglycan, has relatively low amounts of leucine (4.3%). Antisera raised against fetal calf BSP localized the glycoprotein by indirect immunofluorescence to developing bone trabeculae with an overall tissue distribution identical with that of osteonectin. On competition enzyme-linked immunosorbent assay analysis, BSP was 11.5% (+/-2.4%, S.E.) of mineral-bound (guanidine-EDTA-soluble) calf bone protein. Immunoreplicas (Western blots) of calf bone extracts suggest that more than 95% of the antigenicity resided in the Mr = 70,000-80,000 region with the remaining cross-reactivity in Alcian blue positive, Mr = approximately 20,000 and approximately 30,000 bands. Brief treatment of the Mr = 70,000-80,000 species with trypsin produced lower molecular weight, Alcian blue-staining products of similar size. No BSP was detected in guanidine extracts of various soft or unmineralized connective tissues, but dentin contained small amounts (0.4%) of the protein. Rat and fetal human bone were also observed to contain a sialoprotein with similar properties and a certain degree of cross-reactivity with the bovine BSP.

Citing Articles

Exogenous bone sialoprotein improves extraction socket healing in Ibsp knockout and wild-type mice.

Chavez M, Andras N, Tan M, Kolli T, Chu E, Goldberg H Bone. 2024; 192:117381.

PMID: 39722365 PMC: 11761379. DOI: 10.1016/j.bone.2024.117381.


The role of bone sialoprotein in bone healing.

Foster B J Struct Biol. 2024; 216(4):108132.

PMID: 39369971 PMC: 11645215. DOI: 10.1016/j.jsb.2024.108132.


Physicochemical cues are not potent regulators of human dermal fibroblast trans-differentiation.

Ryan C, Pugliese E, Shologu N, Gaspar D, Rooney P, Islam M Biomater Biosyst. 2023; 11:100079.

PMID: 37720487 PMC: 10499661. DOI: 10.1016/j.bbiosy.2023.100079.


Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study.

Reisner A, Blackwell L, Sayeed I, Myers H, Wali B, Heilman S Exp Biol Med (Maywood). 2021; 247(2):145-151.

PMID: 34565198 PMC: 8777475. DOI: 10.1177/15353702211046835.


Relationship between serum osteopontin levels and the severity of COVID-19 infection.

Varim C, Demirci T, Cengiz H, Hacibekiroglu I, Tuncer F, Cokluk E Wien Klin Wochenschr. 2020; 133(7-8):298-302.

PMID: 33369698 PMC: 7768087. DOI: 10.1007/s00508-020-01789-5.